English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases,particularly in myositis, scleroderma and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodiesremains controversial. Studies are lacking in clarifying the association of anti-Ro52 with pulmonary involvement inscleroderma.Objectives: To determine if anti-Ro52 antibodies are associated with pulmonary involvement (interstitial, indirectpulmonary hypertension, or both) in scleroderma.Methods: Single center, retrospective study based on immunoblotting panel analysis and patients clinical records.Pulmonary manifestations were sub-grouped in: 1) interstitial (alveolitis and/or fibrosis), 2) pulmonary artery systolicpressure (PASP) ≥40 mmHg plus interstitial pulmonary disease, and 3) isolated PASP≥40 mmHg (purely vascular).Results: Our scleroderma cohort included 200 patients, of which 137 had immunoblotting panels with anti-Ro52reactivity analysis. The search was conducted between January 2010 and July 2011.The frequency of pulmonary manifestations in patients with positive anti-Ro52 antibodies was 67.7% (n=31), and60% (n=24) in the negative anti-Ro52 group, showing no significant differences between groups (p=0.621).Still no significant differences were found when pulmonary manifestations were evaluated according to thesubgroups (p=0.525).Sensitivity, specificity, positive and negative predictive values of anti-Ro52 reactivity for determining pulmonaryinvolvement in scleroderma were low.Conclusion: No association was found between positive anti-Ro52 antibodies and pulmonary involvement inscleroderma

Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?